HSE wants Pembro for all women with cervical cancer

Professor Michael Barry, who leads the HSE’s Medicines Management Programme, has proposed the introduction of a managed access programme.

Susan Mitchell

Deputy Editor and Health Editor @susmitchellsbp
2nd December, 2018

The HSE wants the state to fund the drug Pembro for more women with cervical cancer.

Professor Michael Barry, who leads the HSE’s Medicines Management Programme, has proposed the introduction of a managed access programme.

Under this proposal, all patients with cervical cancer would be able to access the drug. It typically takes about eight months to see whether individual patients respond to Pembrolizumab, which is called Pembro for short.

Subscribe from just €1 for the first month!

Currency

What's Included

With any subscription you will have access to

  • 971569B3-2C5E-4C45-B798-CEADE16987A8

    Unlimited multi-device access to our iPad, iPhone and Android Apps

  • 099C8662-C57C-42F2-9426-F2F90DF17C8F

    Unlimited access to our eReader library

  • 198AE43B-B9CF-4892-8769-D63C2104BA08

    Exclusive daily insight and opinion seven days a week

  • D8F37B78-25E4-4E4A-A376-4F5789B1564A

    Create alerts to never miss a subject that matters to you

  • B15F2521-37CD-4E02-B898-730A20D39F7F

    Get access to exclusive offers for subscribers on gifts and experiences

  • A564FE02-1AB8-4579-AF9D-BA32A2E5ACA7

    Get content from Business Post, Business Post Magazines, Connected, Tatler and Food & Wine

Share this post

Related Stories

Updated cost of new children’s hospital still ‘confidential’

Hospital group boards to be disbanded to make way for regional health areas

St Vincent’s set to build new €15m intensive care unit

Fertility service opens more clinics to meet ‘20% rise in demand’